[Prognostic significance of EGFR and p53 expression, and angiogenesis in laryngeal squamous cell carcinoma].
To estimate the influence of EGFR, p53, and angiogenesis to the survival of laryngeal cancer patients. Ninety-seven laryngeal cancer patients who received initial treatment at Gifu University Hospital from 1986 to 1996. Patients were classified as follows: T2, 51; T3, 35; T4, 13. Using monoclonal antibodies against EGFR, p53, and factor VIII, respectively, immunohistochemical staining was performed on surgically obtained biopsy specimens. Univariate and multivariate regression analyses in accordance with Cox proportional hazards model were performed to adjust for the possible confounding effects and interactions of each factor. Three different end points, i.e. any death, cancer-related death, and cancer relapse (either local recurrence or distant metastasis), were used to evaluate overall survival, cause-specific survival, and relapse-free survival, respectively. In univariate analysis, sex (P = 0.0052), age (P = 0.0038), T stage (P = 0.0096) and N stage (P = 0.0261) were significantly correlated with overall survival; sex (P = 0.0076), T stage (P = 0.0167) and factor VIII expression (P = 0.0443) were related to cause-specific survival; T stage (P = 0.0005) and EGFR expression (P = 0.0103) were related to relapse-free survival. In multivariate analysis, supraglottis (P = 0.0296) and factor VIII expression (P = 0.0345) were significantly correlated with overall survival; supraglottis (P = 0.0333), T stage (P = 0.0179) and factor VIII expression (P = 0.0134) were significantly correlated with cause-specific survival; T stage (P = 0.0166), chemotherapy (P = 0.0087) and EGFR expression (P = 0.0016) were significantly correlated with relapse-free survival. The present study confirmed that multivariate analysis in accordance with the Cox proportional hazards model revealed that angiogenesis was an independent predictor of overall survival and cause-specific survival, and that EGFR expression was an independent predictor of relapse-free survival in patients with T2, T3 or T4 laryngeal cancer.